Adjunctive aripiprazole, olanzapine, or quetiapine for major depressive disorder: An analysis of number needed to treat, number needed to harm, and likelihood to be helped or harmed

Postgraduate Medicine

Volumn 122, Issue 4, 2010, Pages 39-48

  Citrome, Leslie ^a,b  

^a NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antipsychotic; Aripiprazole; Clinical trials; Likelihood to be helped or harmed; Major depressive disorder; Number needed to harm; Number needed to treat; Olanzapine; Quetiapine

Indexed keywords

ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ESCITALOPRAM; FLUOXETINE; FLUOXETINE PLUS OLANZAPINE; NEUROLEPTIC AGENT; NORTRIPTYLINE; OLANZAPINE; PAROXETINE; PLACEBO; QUETIAPINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE; BENZODIAZEPINE DERIVATIVE; DIBENZOTHIAZEPINE DERIVATIVE; PIPERAZINE DERIVATIVE; QUINOLONE DERIVATIVE;

AKATHISIA; ANALYTIC METHOD; ARTICLE; ATTENTION DISTURBANCE; BLURRED VISION; CONSTIPATION; DOSE RESPONSE; DRUG APPROVAL; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESISTANCE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FATIGUE; HUMAN; HYPERSOMNIA; INCREASED APPETITE; INSOMNIA; LIKELIHOOD TO BE HELPED OR HARMED; MAJOR DEPRESSION; METABOLIC DISORDER; MONOTHERAPY; NUMBER NEEDED TO HARM; NUMBER NEEDED TO TREAT; OUTCOME ASSESSMENT; PATIENT SELECTION; PERIPHERAL EDEMA; REMISSION; RESTLESSNESS; SEDATION; SIDE EFFECT; SOMNOLENCE; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; TREMOR; WEIGHT GAIN; XEROSTOMIA; BIOSTATISTICS; CLINICAL TRIAL; DRUG COMBINATION; POPULATION AND POPULATION RELATED PHENOMENA; REVIEW;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BIOSTATISTICS; CLINICAL TRIALS AS TOPIC; DEPRESSIVE DISORDER, MAJOR; DIBENZOTHIAZEPINES; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; EPIDEMIOLOGIC MEASUREMENTS; HUMANS; PIPERAZINES; QUINOLONES;

EID: 77956626923     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2010.07.2174     Document Type: Article

References (26)

1. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163(1):28-40.
2. Papakostas GI, Thase ME, Fava M, Nelson JC, Shelton RC. Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents. Biol Psychiatry. 2007;62(11):1217-1227.
3. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11): 1905-1917.
4. Judd LL, Akiskal HS, Maser JD, et al. Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse. J Affect Disord. 1998;50(2-3):97-108.
5. Shelton RC, Osuntokun O, Heinloth AN, Corya SA. Therapeutic options for treatment-resistant depression. CNS Drugs. 2010;24(2): 131-161.
6. Abilify (aripiprazole) tablets; Abilify Discmelt (aripiprazole) orally disintegrating tablets; Abilify (aripiprazole) oral solution, Abilify (aripiprazole) injection for intramuscular use only. New York, NY: Bristol-Myers Squibb; Rockville, MD: Otsuka America Pharmaceuticals, Inc. Product label, revised November 2009. http://www.abilify.com/pdf/pi.aspx. Accessed January 2010.
7. Zyprexa (olanzapine) tablet for oral use; Zyprexa Zydis (olanzapine) tablet, orally disintegrating for oral use; Zyprexa intramuscular (olanzapine) injection powder, solution for intramuscular use. Indianapolis, IN: Eli Lilly and Company. Product label, revised December 4, 2009. http://pi.lilly.com/us/zyprexa-pi.pdf. Accessed January 2010.
8. Symbax (olanzapine and fluoxetine hydrochloride) capsule for oral use. Indianapolis, IN: Eli Lilly and Company. Product label, revised August 31, 2009. http://pi.lilly.com/us/symbyax-pi.pdf. Accessed January 2010.
9. Seroquel XR (quetiapine fumarate) extended-release tablets. Product label revised December 2009. Wilmington, DE: AstraZeneca Pharmaceuticals, LP. http://www1.astrazeneca-us.com/pi/seroquelxr.pdf. Accessed January 2010.
10. Citrome L. Compelling or irrelevant? Using number needed to treat can help decide. Acta Psychiatr Scand. 2008;117(6):412-419.
11. Citrome L. Quantifying risk: The role of absolute and relative measures in interpreting risk of adverse reactions from product labels of antipsychotic medications. Curr Drug Saf. 2009;4(3): 229-237.
12. Citrome L, Kantrowitz J. Antipsychotics for the treatment of schizophrenia: likelihood to be helped or harmed, understanding proximal and distal benefits and risks. Expert Rev Neurother. 2008;8(7):1079-1091.
13. Straus SE. Individualizing treatment decisions. The likelihood of being helped or harmed. Eval Health Prof. 2002;25(2):210-224.
14. Berman RM, Fava M, Thase ME, et al. Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spectr. 2009;14(4):197-206.
15. Marcus RN, McQuade RD, Carson WH, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2008;28(2):156-165.
16. Berman RM, Marcus RN, Swanink R, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2007;68(6):843-853.
17. Thase ME, Corya SA, Osuntokun O, et al. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder. J Clin Psychiatry. 2007;68(2):224-236.
18. Shelton RC, Tollefson GD, Tohen M, et al. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry. 2001;158(1):131-134.
19. Shelton RC, Williamson DJ, Corya SA, et al. Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance. J Clin Psychiatry. 2005;66(10): 1289-1297.
20. Corya SA, Williamson D, Sanger TM, et al. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression. Depress Anxiety. 2006;23(6):364-372.
21. Trivedi MH, Thase ME, Osuntokun O, et al. An integrated analysis of olanzapine/fluoxetine combination in clinical trials of treatment-resistant depression. J Clin Psychiatry. 2009;70(3):387-396.
22. Bauer M, Pretorius HW, Constant E, et al. Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study. J Clin Psychiatry. 2009;70(4):540-549.
23. El-Khalili N, Joyce M, Atkinson S, et al. Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study [published online ahead of print February 23, 2010]. Int J Neuropsychopharmacol.
24. Kraemer HC, Kupfer DJ. Size of treatment effects and their importance to clinical research and practice. Biol Psychiatry. 2006;59(11):990-996.
25. Citrome L. Relative vs absolute measures of benefit and risk: what's the difference? Acta Psychiatr Scand. 2010;121(2):94-102.
26. Sackett DL, Rosenberg WM, Gray JA, et al. Evidence based medicine: what it is and what it isn't. BMJ. 1996;312(7023):71-72.